138 related articles for article (PubMed ID: 1331549)
1. Sequential androgen blockade: a biological study in the inhibition of prostatic growth.
Fleshner NE; Trachtenberg J
J Urol; 1992 Dec; 148(6):1928-31. PubMed ID: 1331549
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
[TBL] [Abstract][Full Text] [Related]
3. TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin.
Russo P; Warner JA; Huryk R; Perez G; Heston WD
Prostate; 1994 May; 24(5):237-43. PubMed ID: 8170836
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate.
Rittmaster RS; Magor KE; Manning AP; Norman RW; Lazier CB
Mol Endocrinol; 1991 Jul; 5(7):1023-9. PubMed ID: 1719382
[TBL] [Abstract][Full Text] [Related]
5. Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase.
Juniewicz PE; Barbolt TA; Egy MA; Frenette G; Dube JY; Tremblay RR
Prostate; 1990; 17(2):101-11. PubMed ID: 2169047
[TBL] [Abstract][Full Text] [Related]
6. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs.
Juniewicz PE; Hoekstra SJ; Lemp BM; Barbolt TA; Devin JA; Gauthier E; Frenette G; Dube JY; Tremblay RR
Endocrinology; 1993 Aug; 133(2):904-13. PubMed ID: 8393778
[TBL] [Abstract][Full Text] [Related]
7. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE
Prostate; 1991; 18(3):215-27. PubMed ID: 1850515
[TBL] [Abstract][Full Text] [Related]
8. Vinclozolin and p,p'-DDE alter androgen-dependent gene expression: in vivo confirmation of an androgen receptor-mediated mechanism.
Kelce WR; Lambright CR; Gray LE; Roberts KP
Toxicol Appl Pharmacol; 1997 Jan; 142(1):192-200. PubMed ID: 9007049
[TBL] [Abstract][Full Text] [Related]
9. Effect of the 5 alpha-reductase inhibitor PNU 156765, alone or in combination with flutamide, in the Dunning R3327 prostatic carcinoma model in rats.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Chemotherapy; 1998; 44(4):284-92. PubMed ID: 9681205
[TBL] [Abstract][Full Text] [Related]
10. Combination of an antiandrogen and a 5 alpha-reductase inhibitor: a further step towards total androgen blockade?
Labrie C; Trudel C; Li S; Martel C; Couêt J; Labrie F
Endocrinology; 1991 Jul; 129(1):566-8. PubMed ID: 2055205
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
12. Response of rat ventral prostate to a new and novel 5 alpha-reductase inhibitor.
Brooks JR; Baptista EM; Berman C; Ham EA; Hichens M; Johnston DB; Primka RL; Rasmusson GH; Reynolds GF; Schmitt SM; Arth GE
Endocrinology; 1981 Sep; 109(3):830-6. PubMed ID: 7262023
[No Abstract] [Full Text] [Related]
13. Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA.
Martel C; Trudel C; Couet J; Labrie C; Bélanger A; Labrie F
Mol Cell Endocrinol; 1993 Feb; 91(1-2):43-9. PubMed ID: 8472853
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of antiandrogens in the rat.
Burton S; Trachtenberg J
J Urol; 1986 Oct; 136(4):932-5. PubMed ID: 3761464
[TBL] [Abstract][Full Text] [Related]
15. Effects of flutamide and finasteride on rat testicular descent.
Spencer JR; Torrado T; Sanchez RS; Vaughan ED; Imperato-McGinley J
Endocrinology; 1991 Aug; 129(2):741-8. PubMed ID: 1677329
[TBL] [Abstract][Full Text] [Related]
16. Time-specific androgen blockade with flutamide inhibits testicular descent in the rat.
Husmann DA; McPhaul MJ
Endocrinology; 1991 Sep; 129(3):1409-16. PubMed ID: 1678699
[TBL] [Abstract][Full Text] [Related]
17. Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5alpha-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats.
Kobayashi H; Gotanda K; Shibata Y; Watanabe J; Nakano Y; Shinbo A; Suzuki K
Arzneimittelforschung; 2011; 61(9):515-20. PubMed ID: 22029228
[TBL] [Abstract][Full Text] [Related]
18. Effects of finasteride on the rat ventral prostate.
Shao TC; Kong A; Marafelia P; Cunningham GR
J Androl; 1993; 14(2):79-86. PubMed ID: 8390428
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
[TBL] [Abstract][Full Text] [Related]
20. In utero exposure to antiandrogens alters the responsiveness of the prostate to p,p'-DDE in adult rats and may induce prostatic inflammation.
You L; Brenneman KA; Heck H
Toxicol Appl Pharmacol; 1999 Dec; 161(3):258-66. PubMed ID: 10620483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
